Keeping in range with myLoop
Emmie’s experience with adaptive automated insulin delivery
After trying various therapy options, Emmie met with our mylife team to discuss a possible switch to myLoop: as one of the only licensed loop systems available for children. In just a couple of weeks Emmie and her family have already started to see a positive change to their lives.
Emmie was only 14 months old when she was diagnosed with type 1 diabetes. Family life was turned upside down, Emmie needed several daily injections and her parents had to learn to carb count quickly. After trying out a do-it-yourself loop approach, myLoop arrived just in time for the family to improve everybody’s quality of life. After discussions with Emmies diabetes team, Emmie was able to switch her therapy to myLoop.
When looking back on the beginning of Emmie’s diabetes therapy, Emmie’s parents couldn’t be happier about the outcome:
From now on, Emmie's parents were able to sleep through the night: every time the glucose levels rise the system adjusts accordingly to keep her in range. In the future, this will also allow Emmie to start having sleepovers at friends and family:
Disclaimer
* Approved for people with type 1 diabetes as of two years in combination with Dexcom G6 and four years in combination with FreeStyle Libre 3.The product images are for illustrative purposes only.
mylife and YpsoPump are registered trademarks of Ypsomed AG in several countries.
CamAPS is a registered trademark of CamDiab Ltd.
Dexcom and Dexcom G6 are registered trademarks of Dexcom, Inc. in the United States and/or other countries.
The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott and used with permission.
The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc., and any use of such marks by Ypsomed is under license.Other trademarks are the property of their respective owners.
mylife Loop with Freestyle Libre3/Libre 3 Plus: The innovations described are available in selected countries and expanding to further countries soon. Expansion is contingent upon local regulatory approval.Insulin pumps and Automated Insulin Delivery (AID) systems can improve glucose management but do not remove the risk of diabetic ketoacidosis (DKA). Because these systems use only rapid-acting insulin, any interruption in insulin delivery (e.g., infusion-set failure, occlusion, empty reservoir, or device malfunction) can rapidly lead to ketosis and DKA, even if glucose levels are not markedly elevated.
Healthcare professionals should ensure that users understand the risk of DKA associated with pump and AID therapy, particularly in situations where insulin delivery may be interrupted. Users should be trained to recognise and troubleshoot delivery issues promptly, know when and how to check for ketones and seek urgent medical assistance. Advise to always keep a reliable backup method of insulin delivery available.This information is provided for general educational purposes and is intended for healthcare professionals. It does not replace individual clinical judgement or patient-specific medical advice.